163 related articles for article (PubMed ID: 22142545)
1. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
Yang SW; Smotryski J; McElroy WT; Tan Z; Ho G; Tulshian D; Greenlee WJ; Guzzi M; Zhang X; Mullins D; Xiao L; Hruza A; Chan TM; Rindgen D; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Jan; 22(1):235-9. PubMed ID: 22142545
[TBL] [Abstract][Full Text] [Related]
2. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
[TBL] [Abstract][Full Text] [Related]
5. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Ho GD; Michael Seganish W; Bercovici A; Tulshian D; Greenlee WJ; Van Rijn R; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Apr; 22(7):2585-9. PubMed ID: 22377514
[TBL] [Abstract][Full Text] [Related]
6. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
7. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
[TBL] [Abstract][Full Text] [Related]
9. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
[TBL] [Abstract][Full Text] [Related]
10. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
12. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
13. N-Acylhydrazones as inhibitors of PDE10A.
Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
[TBL] [Abstract][Full Text] [Related]
14. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.
Bartolomé-Nebreda JM; Alonso de Diego SA; Artola M; Delgado F; Delgado Ó; Martín-Martín ML; Martínez-Viturro CM; Pena MÁ; Tong HM; Van Gool M; Alonso JM; Fontana A; Macdonald GJ; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2015 Jan; 58(2):978-93. PubMed ID: 25495129
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
[TBL] [Abstract][Full Text] [Related]
19. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
20. Patented PDE10A inhibitors: novel compounds since 2007.
Kehler J; Kilburn JP
Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]